KDM1A and cancer: A recent review provides a detailed summary of clinical trials of KDM1A inhibitors in other cancers, including small-cell lung cancer, hematologic malignancies, acute myeloid leukemia, myelodysplastic syndromes, Ewing’s sarcoma, solid tumors, myelofibrosis, essential thrombocythemia, prostate cancer, sarcomas, and ovarian-related tumors (please refer to this review for specific details and trial numbers) [191].